The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM The FDA-mandated EF-19 post-approval registry trial studied ...
SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
NovoCure's flagship product, Optune, is a weird-looking, battery-powered hat that generates electric fields in order to disrupt cancer cell division. It's used to treat glioblastoma multiforme (GBM), ...
The Optune device, left, shown with carrying case, connecting cables and electrical arrays that are worn on the patient's head. Credit: Novocure GmbH Electricity has formed the basis of many aspects ...
The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...
Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results